Kymera Therapeutics, Inc. (KYMR) company profile
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
About Kymera Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule therapeutics using targeted protein degradation. The company's technology engages cellular recycling machinery to selectively eliminate disease-causing proteins, particularly historically undrugged transcription factors and scaffolding proteins. Its pipeline centers on immunology programs, including KT-621 targeting STAT6 for inflammatory conditions such as atopic dermatitis and asthma, and KT-579 targeting IRF5 for autoimmune disorders. Kymera also advances partnered programs, including an IRAK4 degrader with Sanofi and cyclin-dependent kinase 2 molecular glue degraders with Gilead Sciences, alongside early-stage oncology research. The company targets patients suffering from immune-inflammatory diseases and cancers.
The company operates without internal manufacturing facilities, outsourcing the production of its drug substances and clinical products to third-party contract manufacturers on a purchase order basis. Kymera’s research and development initiatives address patient populations across the United States, Europe, and Japan. The provided text discusses collaborative agreements and clinical development across these regions, though it does not specify a headquarters location.
Summary of the business section of Kymera Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Kymera Therapeutics, Inc.
- Headquarters
- Watertown, MA
- Address
- 500 North Beacon Street, 4th Floor 02472
- Phone
- (857) 285-5314
- Website
- www.kymeratx.com
- Employees
- 238, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- KYMR
- Exchange
- Nasdaq
- IPO date
- Aug 21, 2020
- Shares outstanding
- 85M, Oct 23, 2026
- Public float
- $2.29B, Dec 31, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1815442
- CUSIP
- 501575104
- ISIN
- US5015751044
- FIGI
- BBG00SDHC8D1
- Share class FIGI
- BBG00SDHC8F9
- EIN
- 81-2992166
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nello Mainolfi | Chief Executive Officer, Director | 666,568 |
| Brian Adams | Chief Legal Officer | 50,254 |
| Terence Rooney | Chief Medical Officer | 38,000 |
| Noah Goodman | Chief Business Officer | 47,179 |
| Bruce N. Jacobs | Chief Financial Officer | 248,083 |
| Jeremy G. Chadwick | Chief Operating Officer | 44,618 |
| Jared Gollob | Chief Medical Officer | 117,134 |
| Ellen Chiniara | Chief Legal Officer | 82,326 |
| Bruce Booth | Director | 2,396,426 |
| Ii Gp Llc Bvf | Director | 2,104,075 |
| Value Fund L. P. Biotechnology | Director | 2,104,075 |
| Gp Holdings Llc Bvf | Director | – |
| Inc/Il Bvf | Director | 2,195,696 |
| I. Gp Llc Bvf | Director | 294,632 |
| Value Fund Ii Lp Biotechnology | Director | 1,671,048 |
| Mark N. Lampert | Director | 2,494,688 |
| Value Trading Fund OS LP Biotechnology | Director | 2,350,503 |
| Partners L. P/Il Bvf | Director | 1,627,928 |
| Partners OS Ltd. BVF | Director | – |
| Jeffrey W. Albers | Director | 5,000 |
| Victor Sandor | Director | – |
| John Maraganore | Director | – |
| 667, L.P. | Director | 5,516,986 |
| Elena Ridloff | Director | 0 |
| Bros. Advisors (GP) LLC Baker | Director | 6,117,295 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $8.55M | $27.85M | $3.77M | $126 | $125 |
| FY2024 | $15.43M | $19.76M | $5.37M | $65 | $93 |
| FY2023 | $9.67M | $6.41M | $4.40M | $41 | $94 |
| FY2022 | $6.93M | -$24.97M | $1.89M | $40 | $90 |
| FY2021 | $11.57M | $12.61M | $3.33M | $102 | $100 |
| FY2020 | $3.68M | $30.95M | $1.81M | $186 | $115 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Nello Mainolfi Founder, President and Chief Executive Officer | $693.00K | – | $7.32M | $519.75K | $14.00K | $8.55M | -45% |
| Bruce Jacobs Chief Financial Officer | $500.00K | $905.10K | $1.20M | $281.25K | $14.00K | $2.90M | -59% |
| Jared Gollob Chief Medical Officer | $507.10K | $905.10K | $1.20M | $285.24K | $14.00K | $2.91M | -49% |
| Noah Goodman Chief Business Officer | $293.99K | $1.05M | $1.63M | $181.73K | $12.79K | $3.17M | – |
| Brian Adams Chief Legal Officer | $145.18K | $2.27M | $3.56M | $90.62K | $6.26K | $6.07M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 21, 2020
- Offer price
- $20.00
- Securities offered
- 8,684,800
- Gross proceeds
- $173.70M
- Exchange
- Nasdaq
- First trading day
- Aug 21, 2020
- First-day close
- $33.26+66.3%
- Lock-up ends (est.)
- Feb 17, 2021
“The initial public offering price is $20.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 238 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 21, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 18, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?